Log In
BCIQ
Print this Print this
 

Relistor, methylnaltrexone (MNTX) (MOA-728, ONO-3849)

  Manage Alerts
Collapse Summary General Information
Company Progenics Pharmaceuticals Inc.
DescriptionPeripheral mu opioid receptor (MOR; OPRM1) antagonist
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationConstipation
Indication DetailsTreat opioid-induced constipation (OIC); Treat opioid-induced constipation (OIC) in patients undergoing orthopedic surgery; Treat opioid-induced constipation (OIC) in patients with chronic non-cancer pain; Treat opioid-induced constipation (OIC) in patients with chronic pain; Treat postoperative ileus (POI) and constipation
Regulatory Designation
PartnerOno Pharmaceutical Co. Ltd.;
Swedish Orphan Biovitrum AB;
Valeant Pharmaceuticals International Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$12,874.0M

$11,749.0M

$290.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today